BioRestorative Therapies Inc (BRTX)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $2.06M
Last updated: Nov 17, 2026 at 11:00 AM ET
BioRestorative Therapies Inc (BRTX) Stock Forecast
Analysts expect BioRestorative Therapies (BRTX) to earn -$13.20 per share in the fiscal year ending Dec 31, 2026, on revenue of $310000. Over the last 30 days, 1 estimate for the fiscal year ending Dec 31, 2026 was revised up and 0 down. For the fiscal year ending Dec 31, 2027, the EPS consensus is -$10.40.
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus shows a smaller loss and revenue estimates rise 383.9%.
- Fiscal year ending Dec 31, 2026
- -$13.20
- EPS consensus, revenue $310000
- Fiscal year ending Dec 31, 2027
- -$10.40
- EPS consensus, revenue $1.50M
- Next report
- Mar 24, 2027
- Estimated
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$13.20 | -$13.20 to -$13.20 | 1 | $310000 | $310000 to $310000 | 1 |
| Dec 31, 2027 | -$10.40 | -$10.40 to -$10.40 | 1 | $1.50M | $1.50M to $1.50M | 1 |
Quarterly Estimates
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$2.04 | -$2.55 to -$1.47 | 4 | $395250 | $98000 to $708750 | 4 |
Estimate Revisions
Across the 2 periods below, the last 30 days brought 2 upward and 0 downward EPS revisions. Raises outnumber cuts in every period.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 1 | 0 |
| Fiscal year ending Dec 31, 2027 | 1 | 0 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has improved from -$27.00.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$13.20 | -$23.40 | -$23.40 | -$27.00 | -$27.00 | N/A |
| Fiscal year ending Dec 31, 2027 | -$10.40 | -$19.40 | -$19.40 | -$25.40 | -$25.40 | N/A |
Frequently Asked Questions About BRTX
What is the BRTX stock forecast?
Consensus analyst estimates put BioRestorative Therapies's EPS at -$13.20 for the fiscal year ending Dec 31, 2026, on revenue of $310000.
What EPS do analysts expect from BRTX next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$13.20, with estimates from -$13.20 to -$13.20 from 1 analyst. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$10.40, with estimates from -$10.40 to -$10.40 from 1 analyst.
What revenue do analysts expect from BioRestorative Therapies next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $310000, with estimates from $310000 to $310000. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $1.50M, with estimates from $1.50M to $1.50M.
How many analysts cover BRTX?
1 analyst estimates EPS for BioRestorative Therapies for the fiscal year ending Dec 31, 2026.
BRTX pages: Overview, Earnings, Forecast, Financials, Competitors